Tabor v. Bodisen Biotech, Inc.

581 F. Supp. 2d 552, 2008 U.S. Dist. LEXIS 106774, 2008 WL 4308427
District Court, S.D. New York·Decided September 18, 2008·No. No. 06 Civ. 13220(VM)·Published·Cited by 1 cases

Opinion

DECISION AND ORDER

VICTOR MARRERO, District Judge.

Plaintiffs brought this action on behalf of a potential class of purchasers of common stock of Bodisen Biotech, Inc. (“Bodi-sen”) between November 3, 2005 and November 10, 2006 (the “Class Period”) against defendants Bodisen, Bo Chen (“Chen”), Wang Chunsheng (“Chun-sheng”), Karen Quiong Wang (“Wang”), Yiliang Lai (“Lai”), and Kabani & Co., Inc. (“Kabani”) (collectively, “Defendants”). Plaintiffs allege violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. § 78a et seq. (the “Exchange Act”) and the Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder, 17 C.F.R. § 240.10b-5.

Bodisen, Chen, Chunsheng, Quiong, and Lai (collectively, “Bodisen Defendants”) move under Federal Rule of Civil Procedure 12(b)(1) (“Rule 12(b)(1)”) to dismiss the Consolidated Amended Class Action Complaint, dated November 16, 2007 (the “Complaint”) for lack of subject matter jurisdiction over the claims of certain potential class members.1 For the reasons discussed below, Bodisen Defendants’ motion to dismiss for lack of subject matter jurisdiction is GRANTED.

I. BACKGROUND2

A. THE PARTIES

1. Plaintiffs

By Order dated August 13, 2007, the Court appointed the Butterfield Trust Group, which includes Anthony S. Butter-field (“Butterfield”)3 and Anteo Quinta-[555]*555valle (“Quintavalle”),4 as lead plaintiffs (“Lead Plaintiffs”). Lead Plaintiffs assert that they bring this action on behalf of a potential class of purchasers of common stock of Bodisen (“Bodisen Shares”) during the Class Period.

2. Bodisen Defendants

On January 14, 2000, Bodisen incorporated in Delaware, with its principal place of business in Xi’an, China. Bodisen purportedly engages in the development, manufacture, and sale of pesticides and compound organic fertilizers in China. Chen, Chunsheng, Wang, and Lai were all officers of Bodisen during the Class Period.

B. BODISEN SHARES

Bodisen’s Shares were initially registered and traded on the National Association of Securities Dealers (“NASD”) Over-the-Counter Bulletin Board. Beginning in 2005, Bodisen “endeavor[ed] to seek dual listing” of its shares on AMEX and AIM in order “to raise growth capital, expand [its] institutional shareholder base and potentially increase [its] product distribution to international markets.” (Compl. ¶ 53 (citing February 6, 2006 Press Release (“February 2006 Press Release”)).) On August 29, 2005, Bodisen transferred its shares from the NASD to the AMEX. Lead Plaintiffs assert that Bodisen Shares reached a Class Period trading high (above twenty dollars per share) in January 2006. In February 2006, Bodisen listed approximately five percent of its shares on AIM (the “AIM Offering”). In March 2006, Bo-disen completed a private offering by which it sold over 5.32 million restricted Bodisen Shares to institutional investors.

On November 6, 2006, Bodisen received a letter from AMEX (the “Delisting Letter”) stating that AMEX had determined that Bodisen was not in compliance with certain AMEX listing standards. On November 12, 2006, Bodisen issued a press release, stating that:

Among other things, AMEX believes that [Bodisen] made insufficient or inaccurate disclosure in its public filings with regard to its relationship with, and payments to, a consultancy firm and its affiliates both prior to and subsequent to its listing on [AMEX], Additionally, ... [AMEX] expressed concern that [Bodi-sen] has internal control issues related to its accounting and financial reporting obligations.

(Id. ¶ 29.) The following day, Bodisen Defendants filed with the SEC, pursuant to Form 8-K, a statement that Bodisen had received the Delisting Letter. Lead Plaintiffs assert that in November 2006 the trading price of Bodisen Shares “collapsed” to below six dollars per share. (Id. ¶ 17.)

In March 2007, according to Lead Plaintiffs, Bodisen Shares were delisted from AMEX because Bodisen

engaged in a pattern and practice of non-compliance with AMEX listing requirements encompassing a broad range of qualitative and corporate governance concerns as well as violations of applicable federal and/or state securities laws ... [Bodisen] has evidenced that it is unable to (I) effectively monitor its compliance with federal and/or state securities laws, as well as AMEX requirements, and (ii) appropriately oversee the [556]*556actions and activities of its consultants, agents and advisors.

(Id. ¶ 31 (citing Notice of Delisting from AMEX, dated March 22, 2007 (the “De-listing Notice”)).) Lead Plaintiffs further assert that, “[fjollowing delisting on [AMEX], while [Bodisen Shares] were frozen in the U.S., [Bodisen Shares] listed in London on [AIM] continued to trade lower, collapsing over 63% in [a] single trading day .... ” (Id. ¶ 102.)

On April 1, 2007, it was reported that “Bodisen would move from [AMEX] to the Over the Counter Market (“OTC”)” and, on the following day, “Bodisen opened trading on the OTC exchange.” (Id. ¶ 106.) Bodisen subsequently published a press release, on March 27, 2007, informing investors that Bodisen had received the Delisting Notice. By July 24, 2007, Bodisen Shares “traded to a low of just above [one dollar] per share.” (Id. ¶ 109.)

C. THE AIM OFFERING

In 2005, Bodisen commenced efforts to obtain listing status on AIM. Bodisen Defendants assert that they took various steps to obtain listing on AIM, including: (1) due diligence in London; (2) retaining Charles Stanley Securities (“Charles Stanley”), a British firm located in London, as its Nominated Advisor (“Nomad”);5 (3) gauging interest in Bodisen Shares; (4) holding road shows (where Bodisen representatives met prospective investors) primarily in the United Kingdom and Hong Kong; (5) preparing, printing and distributing an admission document (the “Admission Document”) (which is similar to a prospectus in the United States); and (6) placing Bodisen Shares with institutional buyers. In addition, New York Global Group (“NYGG”) acted as the United States Corporate Advisor in connection with the AIM Offering.

Bodisen Defendants also assert that Charles Stanley prepared the Admission Document in the United Kingdom, and that Deloitte & Touche U.K. (“Deloitte”) served as the reporting accountant for the AIM Offering, preparing reports on Bodi-sen’s financial condition. Financial statements audited and reviewed by Kabani,6 an independent certified public accounting firm located in California, were attached to the Admission Document. Members of Bodisen’s Board of Directors (the “Board”), located in China and the United States, provided final approval of the Admission Document.

Free access — add to your briefcase to read the full text and ask questions with AI

Tabor v. Bodisen Biotech, Inc., 581 F. Supp. 2d 552, 2008 U.S. Dist. LEXIS 106774, 2008 WL 4308427 (S.D.N.Y. 2008).

581 F. Supp. 2d 552 (Tabor v. Bodisen Biotech, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

TERRA SECURITIES ASA KONKURSBO v. Citigroup, Inc.
688 F. Supp. 2d 303 (S.D. New York, 2010)